Skip to main content

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.

Publication ,  Journal Article
Clark, PJ; Thompson, AJ; McHutchison, JG
Published in: Am J Gastroenterol
January 2011

Genome-wide association studies (GWAS) have recently identified host genetic variation to be critical for predicting treatment response and spontaneous clearance in patients infected with hepatitis C virus (HCV). These important new studies are reviewed and their future clinical implications discussed. Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-λ-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. The good response variant is associated with a twofold increase in the rate of cure. Allele frequencies differ between ethnic groups, largely explaining the observed differences in response rates between Caucasians, African Americans and Asians. IL28B polymorphism is also strongly associated with spontaneous clearance of HCV. The biological mechanisms responsible for these genetic associations remain unknown and are the focus of ongoing research. Knowledge of a patient's IL28B genotype is likely to aid in clinical decision making with standard of care regimens. Future studies will investigate the possibility of individualizing treatment duration and novel regimens according to IL28B type.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Gastroenterol

DOI

EISSN

1572-0241

Publication Date

January 2011

Volume

106

Issue

1

Start / End Page

38 / 45

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Severity of Illness Index
  • Risk Assessment
  • Ribavirin
  • Randomized Controlled Trials as Topic
  • Precision Medicine
  • Polymorphism, Genetic
  • Male
  • Interleukins
  • Interferons
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clark, P. J., Thompson, A. J., & McHutchison, J. G. (2011). IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol, 106(1), 38–45. https://doi.org/10.1038/ajg.2010.370
Clark, Paul J., Alex J. Thompson, and John G. McHutchison. “IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.Am J Gastroenterol 106, no. 1 (January 2011): 38–45. https://doi.org/10.1038/ajg.2010.370.
Clark, Paul J., et al. “IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.Am J Gastroenterol, vol. 106, no. 1, Jan. 2011, pp. 38–45. Pubmed, doi:10.1038/ajg.2010.370.

Published In

Am J Gastroenterol

DOI

EISSN

1572-0241

Publication Date

January 2011

Volume

106

Issue

1

Start / End Page

38 / 45

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Severity of Illness Index
  • Risk Assessment
  • Ribavirin
  • Randomized Controlled Trials as Topic
  • Precision Medicine
  • Polymorphism, Genetic
  • Male
  • Interleukins
  • Interferons